Latent autoimmune diabetes in adults (LADA) should be less latent.
about
Structural Properties of Gene Promoters Highlight More than Two Phenotypes of DiabetesEpidemiology of Fractures in Diabetes.Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional studyAdult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7.Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus.Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the Nord-Trøndelag Health StudyClinical heterogeneity of adult Japanese diabetes depending on titers of glutamic acid decarboxylase autoantibodiesGAD antibody positivity predicts type 2 diabetes in an adult population.Epidemiology of type 1 diabetesPrevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional studyβ-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up.Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetesDiabetic ketoacidosis as first presentation of latent autoimmune diabetes in adultImmunological hypoglycemia associated with insulin antibodies induced by exogenous insulin in 11 Chinese patients with diabetes.Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORDLatent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-RequirementPrevalence and clinical characteristics of recently diagnosed type 2 diabetes patients with positive anti-glutamic Acid decarboxylase antibody.Characteristics and Prevalence of Latent Autoimmune Diabetes in Adults (LADA)Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden.How to diagnose and classify diabetes in primary health care: lessons learned from the Diabetes Register in Northern Sweden (DiabNorth)The Clinical Significance of Glycoprotein Phospholipase D Levels in Distinguishing Early Stage Latent Autoimmune Diabetes in Adults and Type 2 Diabetes.Glutamic acid decarboxylase autoantibodies are dominant but insufficient to identify most Chinese with adult-onset non-insulin requiring autoimmune diabetes: LADA China study 5.LADA: time for a new definition.Immunopathological and genetic features in slowly progressive insulin-dependent diabetes mellitus and latent autoimmune diabetes in adults.Immunomodulation for the prevention of SPIDDM and LADA.ELISA Test for Analyzing of Incidence of Type 1 Diabetes Autoantibodies (GAD and IA2) in Children and AdolescentsGlutamic acid decarboxylase antibodies are indicators of the course, but not of the onset, of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities Study.New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes.GAD65 autoantibody responses in Japanese latent autoimmune diabetes in adult patientsThe rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypesMortality in adult-onset autoimmune diabetes is associated with poor glycemic control: results from the HUNT StudyAssociations between vascular co-morbidities and depression in insulin-naive diabetes patients: the DIAZOB Primary Care Diabetes study.Beta-cell protection and therapy for latent autoimmune diabetes in adults.Diagnostic criteria of latent autoimmune diabetes in adults (LADA): a review and reflection.The multiple origins of Type 1 diabetes.Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy.Antigen-based vaccination and prevention of type 1 diabetes.Islet autoimmunity in phenotypic type 2 diabetes patients.Molecular mechanisms in autoimmune type 1 diabetes: a critical review.Latent autoimmune diabetes of the adult: current knowledge and uncertainty
P2860
Q22065149-D964B336-AF61-47B0-852C-47421A37DDE7Q30248863-C9B126E7-8231-47A3-8A4B-51C0A4C5CA2FQ30414984-E39F9D62-402C-4789-A9E4-152C2EA668B0Q30538087-9E59CCEF-F662-40F0-AC21-386DE1FDA9C9Q33358948-37065A48-B898-46B4-87D2-F4520D82A466Q33556625-E95914B6-2E26-4303-AD78-AD86FF8722FDQ33585748-40DEF8D0-E89A-426E-A22C-AA190C36E237Q33604548-AAB1F3AD-328D-438B-A602-20B3703AF210Q34078199-A09BDD8C-E28D-44C3-B514-59BDC2E72346Q34422172-EBF9EF37-165C-4936-8382-1A2BB40E7745Q34497677-03F8A8A0-456E-464D-BB57-352B1912CBC2Q34718808-B5B63F02-C5CC-41A2-94AC-4CEB7F55F013Q35193550-CD431960-5263-4AAD-90E9-DD8F8815EBF8Q35548380-D35F6D8C-334A-40D3-B28D-3B91A3BABA68Q35561497-40AFD98A-FBEB-4720-96B9-694323CEC15AQ35740110-0ED3E490-3E29-4714-9B34-445539FD193AQ35911077-A31BD3CC-ADB2-4A76-BCF8-5B84B763D5C1Q35919326-7BDB48C5-A0E3-435A-B91A-E936041FFFB2Q35992959-D39A2D5C-30E4-4196-B3BB-31C512542C4EQ36041599-76F14C63-3E05-41A8-9D4C-0C5385A3AB1CQ36062980-86DCE997-7B78-4319-BD4A-3807D667E29CQ36234353-DE367C8C-C4D5-40F7-AAF4-0667CA136D7FQ36560625-B4992E37-15E5-4A80-9011-B2FBFE117C4FQ36666059-E67DE8FF-80B4-45C9-9D51-E22996D1C209Q36666070-5BF322C1-8293-4E4D-AE06-282CBC3F1A6DQ36681606-7501F457-9B61-46A4-89DF-A168D9ACD045Q36711786-DF4277CD-B225-4310-B57A-4BAF8AF5487FQ36714327-E7691A02-1E2A-4E90-A619-FCAADE4E5BCBQ36807416-E828AB32-3852-4115-9443-653C2C1AD2E8Q36807498-DAA78269-3EAD-4FBF-9A0D-76912C54126CQ37331257-BE088CBC-ADD9-4102-AB70-8C20196D89C5Q37348788-A68B3867-531A-463D-98FD-CC7BDB88AF2BQ37624274-4171F853-630F-409C-86D1-C2572095B254Q38030464-A09A30A5-BD4E-428F-8E39-992B87D0944EQ38062580-0298AC97-2D83-411D-AE8B-1D74F3CCAA81Q38071010-9A9B62BA-EB67-4BD3-9EBC-A1DE3647DDEAQ38124273-3AF3A659-46F0-4BAA-A16D-DA7091A975F8Q38134110-005AD511-20AF-47B8-860C-714FD5970256Q38206114-4409FDE5-3BB5-444A-94B4-F7A0AA1EE809Q38324198-5F2DC1D7-3A6A-4BB5-84BB-B277683CF089
P2860
Latent autoimmune diabetes in adults (LADA) should be less latent.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Latent autoimmune diabetes in adults (LADA) should be less latent.
@ast
Latent autoimmune diabetes in adults (LADA) should be less latent.
@en
type
label
Latent autoimmune diabetes in adults (LADA) should be less latent.
@ast
Latent autoimmune diabetes in adults (LADA) should be less latent.
@en
prefLabel
Latent autoimmune diabetes in adults (LADA) should be less latent.
@ast
Latent autoimmune diabetes in adults (LADA) should be less latent.
@en
P2093
P1433
P1476
Latent autoimmune diabetes in adults (LADA) should be less latent.
@en
P2093
Fourlanos S
Greenbaum CJ
Harrison LC
Rolandsson O
P2888
P304
P356
10.1007/S00125-005-1960-7
P577
2005-09-29T00:00:00Z